Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Max S. Topp
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Nicola Goekbuget
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Anthony Selwyn Stein
No relevant relationships to disclose
Ralf C. Bargou
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Hervé Dombret
Research Funding - GRAALL Intergroup
Adele K. Fielding
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Josep M. Ribera
No relevant relationships to disclose
Robin Foà
Consultant or Advisory Role - Amgen
Gerhard Zugmaier
Employment or Leadership Position - Amgen Research Munich GmbH
Stock Ownership - Amgen
Chris Holland
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Tapan Maniar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Birgit Huber
Employment or Leadership Position - Amgen Research (Munich) GmbH
Stock Ownership - Amgen
Dirk Nagorsen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Hagop M. Kantarjian
Research Funding - Amgen